SOL-1 Analysis Highlights Longer Time to Rescue With Axpaxli

Phase 3 data support the durability profile of Axpaxli in patients with neovascular AMD.

By: Patricio G. Schlottmann, MD

Retinal Physician May 8, 2026

5 Key Takeaways

1

The SOL-1 study evaluates Axpaxli against aflibercept in neovascular AMD patients.
2

Patients treated with aflibercept required the first rescue injection at 28 weeks, while those on Axpaxli reached this at 52 weeks.
3

This 6-month delay in rescue injections indicates greater durability for Axpaxli compared to standard treatments.
4

Axpaxli demonstrated a favorable safety profile and maintained stable eye anatomy throughout the study.
5

The findings support Axpaxli's potential as a long-lasting treatment option for neovascular AMD.

Patricio G. Schlottmann, MD

Affiliations: Charles Centro Oftalmológico

Specialties: Ophthalmology

Bio: Patricio G. Schlottmann, MD, is an ophthalmologist associated with Charles Centro Oftalmológico in Argentina. He received his medical degree from the University of Buenos Aires in 1998 and completed formative clinical training at Santa Lucía Hospital in Buenos Aires, Argentina’s largest public eye hospital. Dr. Schlottmann’s work has centered on ophthalmic care, diagnostic technology, and clinical research. His interest in ocular imaging began during specialist training with exposure to Stratus OCT technology, which led to his first publication in Investigative Ophthalmology and Visual Science and helped shape a career combining clinical practice with research.

PentaVision

Retinal Physician

SOL-1 Analysis Highlights Longer Time to Rescue With Axpaxli

5 Key Takeaways

1

2

3

4

5

Recommendations